Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

9.180 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regenxbio Inc

< Previous 1 2 3 4 5 Next >
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
Regenxbio's Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65... 
Via Benzinga
Expert Ratings For Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Regenxbio: Q4 Earnings Insights
Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Earnings Preview: Regenxbio
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial
Regenxbio Inc (NASDAQ: RGNX) announced  
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
Expert Ratings For Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens. Other featured articles discuss the stocks powering 2021... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
REGENXBIO inc (RGNX) Q3 2021 Earnings Call Transcript
RGNX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Earnings Outlook For Regenxbio
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
44 Biggest Movers From Yesterday
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.